Executive Summary
ARGX-121 is an IgA sweeping antibody that achieves rapid and total IgA depletion (~100% reduction) within 7 days, being developed for IgA nephropathy and 3+ potential indications.
ARGX-121
IGA · Antibody (IGA sweeping antibody with IGA-targeting Fab + Fc-ABDEG)
Mechanism of Action[Corp '26 S21]
TypeIgA sweeping antibody
DescriptionARGX-121 uses an IgA-targeting Fab fragment combined with Fc-ABDEG technology to bind and sweep IgA from circulation, achieving rapid and total IgA depletion
DifferentiationFirst IgA sweeping antibody; achieves ~100% IgA depletion within 7 days after single SC dose
Indications: IgA Nephropathy3+ potential indications (not specified)
Target Biology[Corp '26 S21]
IgA is an antibody type that can become pathogenic in diseases like IgA nephropathy, where abnormal IgA deposits in the kidneys cause damage. ARGX-121 sweeps IgA from the blood, potentially halting kidney damage and other IgA-mediated disease processes.
Clinical Data
No clinical trial data available.
Investment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Bull Case
| Thesis Point | Supporting Evidence | Confidence |
|---|---|---|
| Rapid and total IgA depletion is a highly differentiated pharmacological profile | Phase 1 PD data (slide 21) | Low |
Bear Case
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Early stage with no patient data; safety of complete IgA depletion uncertain | Phase 1 only | — |
Market Opportunity[Corp '26 S20]
Patient Population
3+ potential indications
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| Phase 2 study in IgA nephropathy (IgAN) initiation | 2026 | medium | First-in-class IgA-targeting molecule. Large market (IgAN affects ~130K US patients). | — |